BOCA RATON, Fla., Feb. 12 /PRNewswire/ -- The Generic Pharmaceutical Association (GPhA) Board of Directors today named the members of its newly elected Executive Committee and announced the election of William Marth, President and CEO of Teva North America, to serve as its Chairman for 2008- 2009.
Mr. Marth has 30 years of experience in the pharmaceutical industry, including nearly a decade with Teva, which is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. Mr. Marth has served on GPhA's Board of Directors since 2005, most recently as Vice Chair.
"We are very pleased to welcome Bill as GPhA's Chairman of the Board," said Kathleen Jaeger, GPhA President and CEO. "2008 will be an extremely busy year and we look forward to Bill's excellent leadership as we work to increase consumer access to safe, affordable generic medicines.
"We also would like to extend our heartfelt thanks to Bruce Downey for his two years of outstanding service as chairman and for his dedication to the industry."
The GPhA Board also elected Hal Korman, President, North America, Mylan Inc., as its Vice Chairman and re-elected Rosendo Ferran, Senior Consultant, New Chemic, Inc., to serve as its Secretary-Treasurer. Bernhard Hampl, President and CEO, Sandoz US, and Bruce Downey, Chairman and CEO, Barr Pharmaceuticals Inc., will serve as at-large members on the Board's Executive Committee.
GPhA represents the manufacturers and distributors of finished generic
pharmaceuticals, manufacturers and distributors of bulk active
pharmaceutical chemicals, and suppliers of other goods and services to the
generic drug industry. Unbranded and branded generics represent 65% of the
total prescriptions dispensed in the United States, but only 20% of all
dollars spent on prescription drugs. For more information about the
industry, visit http://www.gphaonline.org.
|SOURCE Generic Pharmaceutical Association (GPhA)|
Copyright©2008 PR Newswire.
All rights reserved